In NSCLC, synergy between RT and PD-L1 (nurvalumab) or PD-1 (nivolumab and pembrolizumab) ICIs was observed, with beneficial effects on progression-free survival and overall survival. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.